Tag: pegfilgrastim biosimilars market trends

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Pegfilgrastim Biosimilars Market Set To Climb From $2.04 Billion In 2026 To $2.65 Billion By 2030

The pegfilgrastim biosimilars market size has experienced significant expansion in recent years. It is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be linked to the high cost of originator pegfilgrastim, the limited availability of biosimilars, an expanding cancer patient population, a rise in chemotherapy procedures, and enhanced awareness of neutropenia management.

The pegfilgrastim biosimilars market size is anticipated to demonstrate robust expansion in the coming years. It is projected to grow to $2.65 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This increase during the forecast period can be attributed to the launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, and rising investments in stem cell transplantation therapies. Major trends expected over the forecast period include the increasing use of pegfilgrastim biosimilars in supportive cancer care, the broadening of hospital and retail pharmacy distribution channels, a greater emphasis on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, and rising investments in the treatment of chronic and severe congenital neutropenia.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=70577897&type=smp&name=Pegfilgrastim%20Biosimilars%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pegfilgrastim Biosimilars Market Development Factors: What’s Supporting Demand?

Governmental efforts to advance biosimilar development are anticipated to propel the pegfilgrastim biosimilars market. Authorities globally are prioritizing biosimilar development, primarily due to their cost-effectiveness. In the United States, the Food and Drug Administration (FDA) initiated a Biosimilar Action Plan aimed at broadening treatment options. Concurrently, the Australian government reinforced its commitment to the Biosimilar Awareness Initiative, supporting the Generic and Biosimilar Medicines Association with a $5 million grant to bolster general biosimilar education and promote their appropriate dispensing, prescription, and use. These collective government initiatives, by fostering increased production and awareness of biosimilars, consequently contribute to the expansion of the pegfilgrastim biosimilars market.

Pegfilgrastim Biosimilars Market Segmentation: How Does The Market Break Down By Category?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

Pegfilgrastim Biosimilars Market Transformation Trends: What Innovations Are Driving Change?

Leading companies in the pegfilgrastim biosimilars market are concentrating on technological breakthroughs in biopharmaceuticals, particularly in high-quality biosimilars, to offer safe, effective, and readily available alternatives to original biologic treatments for cancer patients. High-quality biosimilars are defined as biologic medications that closely match the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare enterprise specializing in pharmaceuticals and medical technologies, introduced Stimufend, its inaugural pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is provided as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with an integrated needle guard. Through the combination of advanced biosimilar development and user-friendly delivery, Stimufend signifies a technological leap forward in making superior biologic therapies more widely accessible.

Pegfilgrastim Biosimilars Market Competitive Overview And Top Companies

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

View The Full Pegfilgrastim Biosimilars Market Report:

https://thebusinessresearchcompany.com/report/Pegfilgrastim-Biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pegfilgrastim Biosimilars Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Pegfilgrastim Biosimilars Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for pegfilgrastim biosimilars has shown robust expansion in recent years, with its value projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical growth has been driven primarily by the high expense associated with the original pegfilgrastim product, along with a restricted supply of biosimilar alternatives, a steadily expanding population of cancer patients, a rising frequency of chemotherapy treatments, and heightened awareness regarding effective strategies for managing neutropenia.

The pegfilgrastim biosimilars market is anticipated to experience robust expansion over the coming years, projected to reach $2.65 billion by 2030 with a compound annual growth rate (CAGR) of 6.7%. This forecasted growth is driven by factors such as the introduction of new biosimilars, heightened utilization in supportive oncology care, broader access through hospital and retail pharmacy networks, governmental incentives promoting biosimilar use, and increased funding for stem cell transplantation therapies. Key trends shaping this period encompass the growing adoption of pegfilgrastim biosimilars for supportive cancer treatment, the widening of distribution channels across hospitals and retail pharmacies, a stronger emphasis on mitigating chemotherapy-induced neutropenia, expanded applications in hematopoietic and peripheral blood stem cell transplants, and rising financial commitments to managing chronic and severe congenital neutropenia.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pegfilgrastim Biosimilars Market Growth Drivers And Industry Catalysts

Government-led efforts to advance biosimilar development are anticipated to boost the pegfilgrastim biosimilars market. Due to their cost-effectiveness, various national governments are placing greater emphasis on biosimilar creation. The U.S. Food and Drug Administration (FDA) introduced a Biosimilar Action Plan aimed at broadening available treatment options. The Australian government has reinforced its dedication through the Biosimilar Awareness Initiative, notably by granting $5 million to the Generic and Biosimilar Medicines Association to enhance overall biosimilar education and support activities that encourage proper dispensing, prescription, and usage of biosimilar medicines. Consequently, these governmental initiatives for biosimilar development foster increased production and awareness, which in turn sustains the expansion of the pegfilgrastim biosimilars market.

A rising prevalence of cancer is projected to drive growth in the pegfilgrastim biosimilars market moving forward. Cancer encompasses a set of diseases marked by the uncontrolled proliferation and spread of abnormal cells. The growing incidence of cancer is largely attributed to an aging population, as advanced age represents the most significant risk factor for developing most cancers, with the majority of cases observed in individuals over 65. Pegfilgrastim biosimilars help reduce infection risks in cancer patients during chemotherapy by stimulating white blood cell production. For example, in October 2025, data from the UK-based government health agency, the National Health Service (NHS), revealed 354,820 new cancer diagnoses in 2023, averaging 972 per day, which is 8,605 more than in 2022. As a result, the increasing occurrence of cancer is propelling the pegfilgrastim biosimilars market forward.

Pegfilgrastim Biosimilars Market Segment Breakdown: Which Categories Generate The Most Revenue?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

Pegfilgrastim Biosimilars Market Trends Influencing Long-Term Demand

Leading firms within the pegfilgrastim biosimilars market are investing heavily in biopharmaceutical innovations, particularly the creation of premium biosimilars, to offer cancer patients safer, more effective, and budget-friendly alternatives to original biologic treatments. These high-grade biosimilars are designed to closely mirror the reference product in terms of structure, function, safety, and effectiveness. A notable example occurred in February 2023 when Fresenius Kabi, a German healthcare organization specializing in pharmaceuticals and medical devices, introduced Stimufend—its first pegfilgrastim biosimilar in the United States. This product is intended to prevent and manage chemotherapy-induced neutropenia, supplied as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with an integrated needle guard. Through the integration of sophisticated biosimilar development with a convenient delivery system, Stimufend marks a technological leap forward, enhancing the availability of high-quality biologic medicines.

Pegfilgrastim Biosimilars Market Key Players And Strategic Industry Positioning

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Pegfilgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pegfilgrastim Biosimilars Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Pegfilgrastim Biosimilars Market Increase Between 2026 And 2030?

The pegfilgrastim biosimilars market size has experienced strong growth in recent years. It is anticipated to increase from $1.92 billion in 2025 to $2.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historical growth can be linked to the high cost of originator pegfilgrastim, limited availability of biosimilars, a growing cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is anticipated to show robust expansion over the coming years. It is projected to expand to $2.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This projected growth is driven by the introduction of novel biosimilars, a greater uptake in supportive oncology settings, the enlargement of hospital and retail pharmacy networks, governmental initiatives promoting biosimilar use, and increasing financial commitments to stem cell transplantation therapies. Significant trends during this period involve the increasing integration of pegfilgrastim biosimilars into supportive cancer care, the broadening of hospital and retail pharmacy distribution routes, a heightened priority on alleviating chemotherapy-induced neutropenia, an expansion in hematopoietic and peripheral blood stem cell transplantation applications, and augmented investments in managing chronic and severe congenital neutropenia.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Key Growth Drivers Are Influencing The Pegfilgrastim Biosimilars Market?

Government efforts aimed at developing biosimilars are anticipated to propel the pegfilgrastim biosimilars market. Globally, governments are prioritizing biosimilar development due to their economical benefits. The US Food and Drug Administration (FDA) introduced a Biosimilar Action Plan to expand treatment options. The Australian government is dedicated to the Biosimilar Awareness Initiative, reinforcing this commitment by providing a $5 million grant to the Generic and Biosimilar Medicines Association. This funding supports enhanced general biosimilar education and activities that encourage the appropriate dispensing, prescription, and utilization of biosimilar medicines. As a result, these governmental initiatives for biosimilar development contribute to increased production and awareness, which subsequently fosters the growth of the pegfilgrastim biosimilars market.

What Key Segment Areas Are Included In The Pegfilgrastim Biosimilars Market Assessment?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

Which Trends Are Supporting The Evolution Of The Pegfilgrastim Biosimilars Market?

Major companies active in the pegfilgrastim biosimilars market are concentrating on technological innovation in biopharmaceuticals, such as developing high-quality biosimilars to offer safe, effective, and readily available alternatives to original biologic therapies for cancer patients. High-quality biosimilars are defined as biologic drugs that closely mirror the reference product in terms of structure, function, safety, and efficacy. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is provided as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with a built-in needle guard. By combining advanced biosimilar development with user-friendly delivery, Stimufend represents a technological progression in making high-quality biologic therapies more accessible.

Which Companies Are Influencing The Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Pegfilgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Area Represents The Largest Portion Of The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pegfilgrastim Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Pegfilgrastim Biosimilars Market Be By 2030 Compared To Its 2026 Market Size?

The pegfilgrastim biosimilars market size has experienced significant expansion over recent years. Forecasts indicate it will climb from $1.92 billion in 2025 to $2.04 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.3%. This past growth is attributable to the elevated cost of originator pegfilgrastim, restricted access to biosimilars, an expanding number of cancer patients, increased chemotherapy procedures, and enhanced understanding of neutropenia management.

The pegfilgrastim biosimilars market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this growth during the projected period include the introduction of novel biosimilars, a greater uptake in supportive oncology treatments, the enlargement of hospital and retail pharmacy networks, governmental encouragements for biosimilar utilization, and increased funding for stem cell transplantation therapies. Key trends foreseen in this period encompass the growing acceptance of pegfilgrastim biosimilars in supportive cancer care, the broadening of hospital and retail pharmacy distribution channels, an intensified focus on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation applications, and heightened investments in managing chronic and severe congenital neutropenia.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Factors Are Contributing To The Growth Of The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is anticipated to be driven by government efforts focused on the development of biosimilars. Governments globally are prioritizing biosimilars due to their cost-effectiveness. The US Food and Drug Administration (FDA) initiated a Biosimilar Action Plan to expand treatment options. The Australian government reinforced its commitment to the Biosimilar Awareness Initiative by granting $5 million to the Generic and Biosimilar Medicines Association. This funding supports increased general biosimilar education and activities that promote the appropriate dispensing, prescription, and utilization of biosimilar medicines. Therefore, these governmental initiatives for biosimilar development contribute to enhanced production and awareness, which in turn bolster the growth of the pegfilgrastim biosimilars market. The growing incidence of cancer is expected to fuel the pegfilgrastim biosimilars market moving forward. Cancer refers to a collection of diseases characterized by the uncontrolled multiplication and spread of abnormal cells. The rising prevalence of cancer is linked to an aging population, as advanced age is the most significant risk factor for developing most cancer types, with the majority of cases occurring in individuals over 65 years old. Pegfilgrastim biosimilars are used to lower the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 per day, which was 8,605 more than in 2022. Thus, the increasing incidence of cancer is a significant driver for the pegfilgrastim biosimilars market.

Which Segments Define The Pegfilgrastim Biosimilars Market Segment Structure?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Emerging Trends Are Seen In The Pegfilgrastim Biosimilars Market?

Major companies within the pegfilgrastim biosimilars market are concentrating on technological innovation in biopharmaceuticals, such as developing high-quality biosimilars to offer safe, effective, and readily available alternatives to original biologic therapies for cancer patients. High-quality biosimilars are defined as biologic drugs that closely correspond to the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its initial pegfilgrastim biosimilar in the U.S. Stimufend both prevents and treats chemotherapy-induced neutropenia and is supplied as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard. By integrating advanced biosimilar development with user-friendly delivery, Stimufend signifies a technological advancement in increasing the accessibility of high-quality biologic therapies.

Who Are The Established Players Within The Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Get The Full Pegfilgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Region Is The Largest In The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pegfilgrastim Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Pegfilgrastim Biosimilars Market By 2030 Starting From Its 2026 Size?

The pegfilgrastim biosimilars market size has experienced robust expansion in recent years. This market is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, registering a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historic period can be attributed to the high cost of originator pegfilgrastim, limited availability of biosimilars, a growing cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is projected to experience robust expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $2.65 billion, demonstrating a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is driven by several factors, including the introduction of novel biosimilars, greater acceptance in supportive oncology treatments, broader reach of hospital and retail pharmacy systems, governmental encouragement for biosimilar utilization, and increased funding for stem cell transplantation procedures. Key trends during this period encompass the growing integration of pegfilgrastim biosimilars within supportive cancer regimens, the broadening of hospital and retail pharmacy distribution avenues, a heightened emphasis on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation uses, and escalating investments in managing chronic and severe congenital neutropenia.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Drivers Are Shaping The Future Growth Of The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market is anticipated to be driven by government initiatives focused on the development of biosimilars. Governments globally are prioritizing biosimilar development due to their cost-effectiveness. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan to enhance treatment options. The Australian government demonstrates its commitment to the Biosimilar Awareness Initiative by providing a grant of $5 million to the Generic and Biosimilar Medicines Association, aiming to facilitate increased general biosimilar education and activities promoting the suitable dispensing, prescription, and use of biosimilar medicines. Therefore, government efforts directed towards biosimilar development contribute to increased production and awareness, which in turn support the growth of the pegfilgrastim biosimilars market.

Which Segment Categories Define The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Major Market Trends Are Driving Changes In The Pegfilgrastim Biosimilars Market?

Companies operating within the pegfilgrastim biosimilars market are prioritizing technological advancements in biopharmaceuticals, specifically focusing on developing high-quality biosimilars to offer safe, effective, and accessible alternatives to original biologic therapies for cancer patients. These high-quality biosimilars are biologic drugs designed to closely resemble the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company known for pharmaceuticals and medical technologies, launched Stimufend, its inaugural pegfilgrastim biosimilar, in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with an integrated needle guard. This product signifies a technological step forward, combining advanced biosimilar development with user-friendly delivery to enhance the accessibility of high-quality biologic therapies.

Who Are The Top Companies Competing In The Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Read the full pegfilgrastim biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Geographic Regions Are Influencing Demand In The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pegfilgrastim Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pegfilgrastim biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Pegfilgrastim Biosimilars Market in 2030?

The pegfilgrastim biosimilars market has demonstrated robust expansion in its size over recent years. It is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be attributed to factors such as the high cost of originator pegfilgrastim, limited availability of biosimilars, an expanding cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is projected to experience robust expansion over the coming years. This market is anticipated to reach $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the forecast period include the introduction of novel biosimilars, wider integration into supportive oncology treatments, the expansion of hospital and retail pharmacy distribution channels, governmental encouragement for biosimilar utilization, and increased funding for stem cell transplantation therapies. Key trends expected over the forecast period encompass the growing integration of pegfilgrastim biosimilars in supportive cancer management, the expansion of hospital and retail pharmacy distribution networks, a heightened emphasis on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation applications, and greater financial commitment towards addressing chronic and severe congenital neutropenia.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Drivers Are Influencing Production Trends In The Pegfilgrastim Biosimilars Market?

Government initiatives promoting the development of biosimilars are projected to propel the pegfilgrastim biosimilars market. Global governments are increasingly prioritizing biosimilar development due to their cost-effectiveness. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan aimed at increasing available treatment options. Furthermore, the Australian government strengthened its commitment to the Biosimilar Awareness Initiative by granting $5 million to the Generic and Biosimilar Medicines Association to support expanded general biosimilar education and activities that encourage appropriate dispensing, prescription, and utilization of biosimilar medicines. These government initiatives for biosimilar development consequently boost production and awareness, thereby fostering the growth of the pegfilgrastim biosimilars market.

Which Segment Groups Are Influencing The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Trends Are Reshaping The Dynamics Of The Pegfilgrastim Biosimilars Market?

Companies active in the pegfilgrastim biosimilars market are concentrating on technological innovation within biopharmaceuticals, specifically creating high-quality biosimilars to offer safe, effective, and accessible alternatives to original biologic therapies for cancer patients. These high-quality biosimilars are biologic drugs that closely resemble the reference product in structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, introduced Stimufend, its initial pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with a built-in needle guard. By combining advanced biosimilar development with user-friendly delivery, Stimufend represents a technological advancement in improving access to high-quality biologic therapies.

Who Are The Prominent Global Companies Shaping The Pegfilgrastim Biosimilars Market Landscape?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pegfilgrastim Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pegfilgrastim biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Pegfilgrastim Biosimilars Market in 2030?

The pegfilgrastim biosimilars market has demonstrated robust expansion in its size over recent years. It is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be attributed to factors such as the high cost of originator pegfilgrastim, limited availability of biosimilars, an expanding cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is projected to experience robust expansion over the coming years. This market is anticipated to reach $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. Factors driving this growth during the forecast period include the introduction of novel biosimilars, wider integration into supportive oncology treatments, the expansion of hospital and retail pharmacy distribution channels, governmental encouragement for biosimilar utilization, and increased funding for stem cell transplantation therapies. Key trends expected over the forecast period encompass the growing integration of pegfilgrastim biosimilars in supportive cancer management, the expansion of hospital and retail pharmacy distribution networks, a heightened emphasis on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation applications, and greater financial commitment towards addressing chronic and severe congenital neutropenia.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Drivers Are Influencing Production Trends In The Pegfilgrastim Biosimilars Market?

Government initiatives promoting the development of biosimilars are projected to propel the pegfilgrastim biosimilars market. Global governments are increasingly prioritizing biosimilar development due to their cost-effectiveness. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan aimed at increasing available treatment options. Furthermore, the Australian government strengthened its commitment to the Biosimilar Awareness Initiative by granting $5 million to the Generic and Biosimilar Medicines Association to support expanded general biosimilar education and activities that encourage appropriate dispensing, prescription, and utilization of biosimilar medicines. These government initiatives for biosimilar development consequently boost production and awareness, thereby fostering the growth of the pegfilgrastim biosimilars market.

Which Segment Groups Are Influencing The Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Trends Are Reshaping The Dynamics Of The Pegfilgrastim Biosimilars Market?

Companies active in the pegfilgrastim biosimilars market are concentrating on technological innovation within biopharmaceuticals, specifically creating high-quality biosimilars to offer safe, effective, and accessible alternatives to original biologic therapies for cancer patients. These high-quality biosimilars are biologic drugs that closely resemble the reference product in structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, introduced Stimufend, its initial pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with a built-in needle guard. By combining advanced biosimilar development with user-friendly delivery, Stimufend represents a technological advancement in improving access to high-quality biologic therapies.

Who Are The Prominent Global Companies Shaping The Pegfilgrastim Biosimilars Market Landscape?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pegfilgrastim Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model